Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | GAA | P10253 | 6/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.45 |
| ▸ | GLA | P06280 | 2/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CFTR | P13569 | 3/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.40 |
| ▸ | IKBKB | O14920 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL913269 | 0.82 | KDM4E (0.49) | KDM4EALDH1A1GAAMAPTHPGD | |
| SCHEMBL28406632 | 0.82 | CES2 (0.42) | KDM4EALDH1A1GAAMAPTTSHR | |
| SCHEMBL4014982 | 0.82 | KDM4E (0.49) | KDM4EALDH1A1GAAMAPTHPGD | |
| SCHEMBL505595 | 0.82 | KDM4E (0.49) | KDM4EALDH1A1GAAMAPTHPGD | |
| SCHEMBL29579072 | 0.81 | KDM4E (0.47) | KDM4EALDH1A1GAAMAPTHPGD | |
| SCHEMBL204027 | 0.81 | KDM4E (0.47) | KDM4EALDH1A1GAAMAPTHPGD | |
| SCHEMBL31719787 | 0.81 | SOS1 (0.41) | KDM4EALDH1A1GAAMAPTHPGD | |
| SCHEMBL3575890 | 0.81 | KDM4E (0.47) | KDM4EALDH1A1GAAMAPTHPGD | |
| SCHEMBL28474614 | 0.81 | SOS1 (0.41) | KDM4EALDH1A1GAAMAPTHPGD | |
| SCHEMBL25612469 | 0.81 | KDM4E (0.47) | KDM4EALDH1A1GAAMAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250092040-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2025-03-20 | — | — | US | disclosed |
| US-20240239797-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-11999730-B1 | AKT1 modulators | ALTEROME THERAPEUTICS, INC. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240174667-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. | 2024-05-30 | — | — | US | disclosed |
| WO-2024073371-A1 | AKT1 MODULATORS | ALTEROME THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| EP-3341375-B1 | PROCESS FOR PREPARING PARP INHIBITOR, CRYSTALLINE FORMS, AND USES THEREOF | BEIGENE LTD (KY) | 2022-04-13 | — | — | EP | disclosed |
| EP-3315500-B1 | FUSED TETRA OR PENTA-CYCLIC DIHYDRODIAZEPINOCARBAZOLONES AS PARP INHIBITORS | BEIGENE LTD (KY) | 2020-03-18 | — | — | EP | disclosed |
| US-10457680-B2 | Process for preparing a PARP inhibitor, crystalline forms, and uses thereof | BEIGENE, LTD. (KY) | 2019-10-29 | — | — | US | disclosed |
| US-20190177325-A1 | PROCESS FOR PREPARING A PARP INHIBITOR, CRYSTALLINE FORMS, AND USES THEREOF | BEONE MEDICINES I GMBH (CH) | 2019-06-13 | — | — | US | disclosed |
| US-20190016731-A1 | FUSED TETRA OR PENTA-CYCLIC DIHYDRODIAZEPINOCARBAZOLONES AS PARP INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2019-01-17 | — | — | US | disclosed |
| CN-106220635-A | As the Fourth Ring condensed of PARP inhibitor or the dihydro diaza * at five rings carbazole ketone | 百济神州有限公司 | 2016-12-14 | — | — | CN | disclosed |
| CN-103703004-B | Fused tetracyclic or pentacyclic dihydrodiaza-carbazolones as PARP inhibitors | 百济神州有限公司 | 2016-06-29 | — | — | CN | disclosed |
| US-20160159811-A1 | FUSED TETRA OR PENTA-CYCLIC DIHYDRODIAZEPINOCARBAZOLONES AS PARP INHIBITORS | BEIGENE SWITZERLAND GMBH (CH) | 2016-06-09 | — | — | US | disclosed |
| US-9328111-B2 | Substituted cycloocta[5,6]pyrido[4,3,2-de]phthalazines as PARP inhibitors | BEIGENE LTD. (KY) | 2016-05-03 | — | — | US | disclosed |
| US-9260440-B2 | Fused tetra or penta-cyclic dihydrodiazepinocarbazolones as PARP inhibitors | BEIGENE, LTD. (KY) | 2016-02-16 | — | — | US | disclosed |
| US-20150175617-A1 | FUSED TETRA OR PENTA-CYCLIC DIHYDRODIAZEPINOCARBAZOLONES AS PARP INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2015-06-25 | — | — | US | disclosed |
| EP-2797921-A1 | FUSED TETRA OR PENTA-CYCLIC DIHYDRODIAZEPINOCARBAZOLONES AS PARP INHIBITORS | Beigene, Ltd. (KY) | 2014-11-05 | — | — | EP | disclosed |
| EP-2797919-A1 | FUSED TETRA OR PENTA-CYCLIC PYRIDOPHTHALAZINONES AS PARP INHIBITORS | BeiGene, Ltd. (KY) | 2014-11-05 | — | — | EP | disclosed |
| WO-2013097225-A1 | FUSED TETRA OR PENTA-CYCLIC DIHYDRODIAZEPINOCARBAZOLONES AS PARP INHIBITORS | BEIGENE, LTD. (KY) | 2013-07-04 | — | — | WO | disclosed |
| WO-2013097226-A1 | FUSED TETRA OR PENTA-CYCLIC PYRIDOPHTHALAZINONES AS PARP INHIBITORS | BEIGENE, LTD. (KY) | 2013-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239797-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | KDM4E 2376/4885ALDH1A1 4692/4885GAA 1988/4885 |
| US-20190016731-A1 | FUSED TETRA OR PENTA-CYCLIC DIHYDRODIAZEPINOCARBAZOLONES AS PARP INHIBITORS | PARP1, PARP2, PARP4 | KDM4E 2269/4885ALDH1A1 1546/4885GAA 3219/4885 |
| US-20150175617-A1 | FUSED TETRA OR PENTA-CYCLIC DIHYDRODIAZEPINOCARBAZOLONES AS PARP INHIBITORS | PARP1, PARP2, PARP4 | KDM4E 2079/4885ALDH1A1 1740/4885GAA 3210/4885 |
| US-20160159811-A1 | FUSED TETRA OR PENTA-CYCLIC DIHYDRODIAZEPINOCARBAZOLONES AS PARP INHIBITORS | PARP1, PARP2, PARP4 | KDM4E 2079/4885ALDH1A1 1740/4885GAA 3210/4885 |
| US-20190177325-A1 | PROCESS FOR PREPARING A PARP INHIBITOR, CRYSTALLINE FORMS, AND USES THEREOF | PARP1, PARP2, PARP11 | KDM4E 833/4885ALDH1A1 1851/4885GAA 2914/4885 |
| US-10457680-B2 | Process for preparing a PARP inhibitor, crystalline forms, and uses thereof | PARP1, PARP2, PARP11 | KDM4E 833/4885ALDH1A1 1851/4885GAA 2914/4885 |
| US-20250092040-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | KDM4E 2376/4885ALDH1A1 4692/4885GAA 1988/4885 |
| US-11999730-B1 | AKT1 modulators | AKT1S1, AKT1, AKT2 | KDM4E 2376/4885ALDH1A1 4692/4885GAA 1988/4885 |
| US-20240174667-A1 | AKT1 MODULATORS | AKT1S1, AKT1, AKT2 | KDM4E 2376/4885ALDH1A1 4692/4885GAA 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.